Proteogenomics and Cancer Risk: From Discovery to Prevention

Proteogenomics and Cancer Risk: From Discovery to Prevention

Wednesday, October 9, 2024 12:45 PM to 1:05 PM · 20 min. (Europe/Brussels)
Big Data in Oncology
Presentation
Theatre 8

Information

Discover how circulating proteins reveal key pathways in cancer and help identify therapeutic targets for prevention. Join us as Karl presents data from EPIC and the UK Biobank, exploring proteomic and genetic variation in cancer risk, and how to follow up on potentially aetiological proteins for cancer prevention.

Olink ProteomicsBooth 610Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, focusing strongly on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to developing our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways. www.olink.com

Registered attendees

Adrian Mateianu
Adrian Mateianu
Head of Biomedical Data ScienceNagarro
Carmen Miguel
Carmen Miguel
Legal Director, Data PrivacyAlnylam
Christopher Woodward
Christopher Woodward
Senior Product ManagerApheris

Log in